Factors correlated with adherence to HAART: a multicentre study from an HIV-infected Greek population
Abstract number: 1733_1415
Pitsounis N., Peristeraki S., Tsogas N., Mangafas N., Chini M., Lioni A., Skoutelis A., Nikolaides P., Gargalianos P., Panos G., Kordosis T., Paparizos V., Gikas A., Moschou M., Chrysos G., Koratzanis G., Lazanas M.
Objectives: Poor adherence to HAART can result in treatment failure and the development of resistant strains of HIV. We examined the association between adherence to HAART and various factors in an HIV infected population.
Methods: A structured questionnaire was distributed to the patients regularly attending 11 Infectious Diseases Units in Greece (~2200 patients). Adherence to HAART was measured by self report. A single question measuring frequency of dose omission within the previous 4 months was administered. Adherence was defined as <10% of doses missed. Statistical analysis involved non parametric correlations (Spearman's-Rho and Pearson's c2). Statistical significance was set at 0.05.
Results: 482 patients completed the questionnaire, of whom 409 (84.9%) were male and 73 (15.1%) were female. Mean age was 41 years (range 2080 years). Age, gender, adjustment to their new health status, satisfaction with the number of pills taken and psychological support received were not associated with adherence.
Factors correlated with adherence were length of known HIV infection (rho = -0.16, p = 0.002), length of antiretroviral treatment (rho = -0.13, p = 0.001), side effects of HAART (rho = -0.11, p = 0.0035), belief about radical cure for HIV infection (rho = 0.11, p = 0.0034), and frequency of condom use (rho = 0.14, p = 0.010).
Conclusion: Adherence to HAART correlates behaviorally positively with the use of condoms (indicating risk aversion), as well as psychologically positively with optimism about radical cure for HIV. Simultaneously adherence to HAART is negatively correlated with disease duration, measured by length of HIV seropositivity and length of treatment, as well as with occurrence of side effects from HAART.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|